Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer

NCT07155629 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

381

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer Resectable

Interventions

DRUG: mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine

Sponsor

Helsinki University Central Hospital

Collaborators

[object Object]